Theravance Biopharma (NASDAQ:TBPH) Upgraded to Buy by BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Theravance Biopharma (NASDAQ:TBPH) from a hold rating to a buy rating in a research report sent to investors on Tuesday, July 30th, BidAskClub reports.

A number of other equities analysts have also recently issued reports on the company. Piper Jaffray Companies reiterated a positive rating and issued a $55.00 price objective on shares of Theravance Biopharma in a report on Wednesday, June 19th. Cantor Fitzgerald reiterated a buy rating and issued a $55.00 price objective on shares of Theravance Biopharma in a report on Friday, April 12th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Theravance Biopharma currently has a consensus rating of Buy and an average price target of $44.25.

Theravance Biopharma stock opened at $21.27 on Tuesday. Theravance Biopharma has a 52 week low of $15.18 and a 52 week high of $35.48. The business has a 50-day simple moving average of $18.58 and a 200 day simple moving average of $21.23. The stock has a market cap of $1.20 billion, a price-to-earnings ratio of -5.33 and a beta of 1.75.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.72) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.22) by $0.50. Theravance Biopharma had a negative return on equity of 2,631.15% and a negative net margin of 369.67%. The business had revenue of $26.15 million during the quarter, compared to analysts’ expectations of $13.92 million. Equities research analysts predict that Theravance Biopharma will post -4.28 EPS for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of TBPH. Norges Bank bought a new stake in shares of Theravance Biopharma in the 4th quarter valued at about $22,422,000. Nuveen Asset Management LLC bought a new stake in shares of Theravance Biopharma in the 2nd quarter valued at about $3,610,000. Nomura Holdings Inc. lifted its stake in shares of Theravance Biopharma by 250.0% in the 2nd quarter. Nomura Holdings Inc. now owns 210,000 shares of the biopharmaceutical company’s stock valued at $3,562,000 after acquiring an additional 150,000 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Theravance Biopharma by 3.1% in the 2nd quarter. BlackRock Inc. now owns 3,832,682 shares of the biopharmaceutical company’s stock valued at $62,587,000 after acquiring an additional 116,009 shares during the last quarter. Finally, Fosun International Ltd bought a new stake in shares of Theravance Biopharma in the 1st quarter valued at about $2,386,000. Hedge funds and other institutional investors own 83.83% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.

Featured Story: What are Bollinger Bands?

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.